Gene expression profile of immune-check point in response to Trastuzumab therapy in patients with HER-2 positive breast cancer.
Wiad Lek
; 77(5): 1056-1062, 2024.
Article
en En
| MEDLINE
| ID: mdl-39008597
ABSTRACT
OBJECTIVE:
Aim:
To clarify the association between response to Trastuzumab and molecular expression of TIM-3 and FOXP-3 immune checkpoints. PATIENTS ANDMETHODS:
Materials andMethods:
FOXP-3 and TIM-3 expression in peripheral blood was analyzed using qPCR, and the serum level of Trastuzumab was estimated using an immune sorbent enzyme assay.RESULTS:
Results:
During treatment with Trastuzumab, the FOXP-3 gene expression showed a significant decline throughout one year of treatment, going from 0.85 at cycle 9 to 0.75 at cycle 17. While the TIM-3 gene expression showed a significant up regulation at cycle 9 to 2.8 fold, followed by a reduction in the fold change from 2.8 to 1.7 in the font of reference gene expression.CONCLUSION:
Conclusions:
FOXP-3 and TIM-3 have the potential to be suggestive markers that can anticipate the response to Trastuzumab, but they are not capable of predicting the likelihood of recurrence.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Receptor ErbB-2
/
Trastuzumab
Límite:
Adult
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Wiad Lek
Asunto de la revista:
MEDICINA
Año:
2024
Tipo del documento:
Article
País de afiliación:
Irak
Pais de publicación:
Polonia